Nuevolution AB (publ) announces timing for the release and webcast of the third quarter 2018 interim results

Stockholm, 21 November 2018 – Nuevolution AB (publ) (NUE.ST) announces today that it will report its interim report for the third quarter 2018 on Wednesday, 28 November after 18:00 CET.

On Thursday, 29 November at 9:00 CET, the company’s executive management will host a live video presentation and discussion at Redeye in Stockholm of the results and provide an update on the pipeline programs and partnering activities. Access to the event can be obtained through the following link:

LIVE access on Thursday 29 November at 9:00 CET

https://www.redeye.se/live/nuevolution-q3-2018 

REPLAY access

Video replay will be available at www.nuevolution.com in the Investors section, and at Redeye.se.

For more information, please contact:

Alex Haahr Gouliaev, CEO

Phone: +45 3913 0902

Email: ahg@nuevolution.com

Johnny Stilou, CFO

Phone: +45 8877 5973

Email: jost@nuevolution.com

Information about Nuevolution AB (publ)

Nuevolution AB (publ) is a leading small molecule drug discovery biotech company founded in 2001, and headquartered in Copenhagen, Denmark. Nuevolution partners its discovery platform and programs with pharmaceutical and biotechnology companies to seek future benefit of patients in need of novel medical treatment option. Nuevolution’s internal programs are focused on therapeutically important targets within inflammation, oncology and immuno-oncology.

The information was sent for publication, through the agency of the contact persons set out above, on Wednesday 21 November 2018, 18:00 CET.

Nuevolution AB (publ) is listed at Nasdaq in Stockholm, Sweden (ticker: NUE). More information about Nuevolution can be found on: www.nuevolution.com  

About Us

Nuevolution is a biotechnology company with a unique business model, where continuous revenue generation and risk mitigation represent primary objectives. This strategy is executed by a “multiple shots at goal” approach in combination with reduced research costs, where simultaneous development of multiple programs in parallel is made possible. Nuevolution is the inventor of Chemetics®. Chemetics® is a patent protected drug discovery research platform, which enables identification of small molecule (tablet based) drug candidates much more effectively and at lower cost than what is possible by other conventional methods. Nuevolution applies its research platform for the identification and development of its own pipeline of drug candidates for treatment of cancer and chronic inflammatory diseases Nuevolution applies a business model that is unique for a biotechnology company with a primary focus on revenue generation and risk minimization (i.e. lower cost development) by having a number of programs developed in parallel. Nuevolution is the inventor of Chemetics® , a patent protected drug discovery platform which enables efficient discovery of novel chemical small molecule leads for specific indications addressing disease targets within the company’s therapeutic focus areas

Subscribe

Documents & Links